Development and Application of a High Throughput Methodology to Characterize and Formulate Protein-Based Therapeutics

[1]  Wei Wang,et al.  Protein aggregation--pathways and influencing factors. , 2010, International journal of pharmaceutics.

[2]  A. Ferrante,et al.  Inhibition of human polymorphonuclear leukocyte respiratory burst, bactericidal activity, and migration by pneumolysin , 1983, Infection and immunity.

[3]  S. Leppla,et al.  The roles of anthrax toxin in pathogenesis. , 2004, Current opinion in microbiology.

[4]  Huanchun Chen,et al.  Investigation of New Dominant-Negative Inhibitors of Anthrax Protective Antigen Mutants for Use in Therapy and Vaccination , 2009, Infection and Immunity.

[5]  C Russell Middaugh,et al.  Improved data visualization techniques for analyzing macromolecule structural changes , 2012, Protein science : a publication of the Protein Society.

[6]  W. Weissenhorn,et al.  Filovirus assembly and budding. , 2006, Virology.

[7]  B. Sellman,et al.  Dominant-Negative Mutants of a Toxin Subunit: An Approach to Therapy of Anthrax , 2001, Science.

[8]  C. Leclerc,et al.  Virus-like particles: a new family of delivery systems , 2002, Expert review of vaccines.

[9]  R. Tweten,et al.  Only two amino acids are essential for cytolytic toxin recognition of cholesterol at the membrane surface , 2010, Proceedings of the National Academy of Sciences.

[10]  B. Narasimhan,et al.  Vaccine adjuvants: current challenges and future approaches. , 2009, Journal of pharmaceutical sciences.

[11]  Vidyashankara G. Iyer,et al.  Formulation development of a plant-derived h1n1 influenza vaccine containing purified recombinant hemagglutinin antigen , 2012, Human vaccines & immunotherapeutics.

[12]  B. Carpick,et al.  Structure-guided Antigen Engineering Yields Pneumolysin Mutants Suitable for Vaccination against Pneumococcal Disease , 2011, The Journal of Biological Chemistry.

[13]  Satoshi Ohtake,et al.  Trehalose: current use and future applications. , 2011, Journal of pharmaceutical sciences.

[14]  J. Bann,et al.  Anthrax toxin protective antigen—Insights into molecular switching from prepore to pore , 2012, Protein science : a publication of the Protein Society.

[15]  K. Griebenow,et al.  Effect of excipients on the stability and structure of lyophilized recombinant human growth hormone. , 1998, Journal of pharmaceutical sciences.

[16]  Nathaniel R Maddux,et al.  An improved methodology for multidimensional high-throughput preformulation characterization of protein conformational stability. , 2012, Journal of pharmaceutical sciences.

[17]  John A. Young,et al.  Anthrax toxin. , 2003, Annual review of cell and developmental biology.

[18]  J. Paton,et al.  Effect of immunization with pneumolysin on survival time of mice challenged with Streptococcus pneumoniae , 1983, Infection and immunity.

[19]  S. Shadomy,et al.  Use of anthrax vaccine in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. , 2010, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[20]  S. Joshi,et al.  Multidimensional methods for the formulation of biopharmaceuticals and vaccines. , 2011, Journal of pharmaceutical sciences.

[21]  T. Mitchell,et al.  Streptococcus pneumoniae: virulence factors and variation. , 2010, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[22]  T. Noda,et al.  Short Communication Characterization of the Ebola virus nucleoprotein- RNA complex , 2010 .

[23]  Hardeep S Samra,et al.  Advancements in high throughput biophysical technologies: applications for characterization and screening during early formulation development of monoclonal antibodies. , 2012, Molecular pharmaceutics.

[24]  R. Tweten,et al.  Specific Protein-Membrane Contacts Are Required for Prepore and Pore Assembly by a Cholesterol-dependent Cytolysin* , 2007, Journal of Biological Chemistry.

[25]  G. Böhm,et al.  Quantitative analysis of protein far UV circular dichroism spectra by neural networks. , 1992, Protein engineering.

[26]  Shinji Watanabe,et al.  Functional Importance of the Coiled-Coil of the Ebola Virus Glycoprotein , 2000, Journal of Virology.

[27]  Yoshihiro Kawaoka,et al.  Functional Mapping of the Nucleoprotein of Ebola Virus , 2006, Journal of Virology.

[28]  B. Chang,et al.  Preferential exclusion of sucrose from recombinant interleukin-1 receptor antagonist: role in restricted conformational mobility and compaction of native state. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[29]  D. E. Anderson,et al.  Effect of 2-fluorohistidine labeling of the anthrax protective antigen on stability, pore formation, and translocation. , 2007, Biochemistry.

[30]  A. Ferrante,et al.  Inhibition of in vitro human lymphocyte response by the pneumococcal toxin pneumolysin , 1984, Infection and immunity.

[31]  D. Burton,et al.  Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor , 2008, Nature.

[32]  T. Mitchell,et al.  Construction and Immunological Characterization of a Novel Nontoxic Protective Pneumolysin Mutant for Use in Future Pneumococcal Vaccines , 2006, Infection and Immunity.

[33]  C Russell Middaugh,et al.  Derivative absorbance spectroscopy and protein phase diagrams as tools for comprehensive protein characterization: a bGCSF case study. , 2003, Journal of pharmaceutical sciences.

[34]  S. Joshi,et al.  Investigation of protein conformational stability employing a multimodal spectrometer. , 2011, Analytical chemistry.

[35]  T. Vedvick,et al.  Conformational Stability and Disassembly of Norwalk Virus-like Particles , 2006, Journal of Biological Chemistry.

[36]  J. Mekalanos,et al.  Combining Anthrax Vaccine and Therapy: a Dominant-Negative Inhibitor of Anthrax Toxin Is Also a Potent and Safe Immunogen for Vaccines , 2005, Infection and Immunity.

[37]  P. S. Kim,et al.  Core structure of the envelope glycoprotein GP2 from Ebola virus at 1.9-A resolution. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[38]  J. Paton,et al.  Comparative efficacy of autolysin and pneumolysin as immunogens protecting mice against infection by Streptococcus pneumoniae. , 1992, Microbial pathogenesis.

[39]  P. Andrew,et al.  Immunization of mice with pneumolysin toxoid confers a significant degree of protection against at least nine serotypes of Streptococcus pneumoniae , 1994, Infection and immunity.

[40]  R. Bhat,et al.  Why Is Trehalose an Exceptional Protein Stabilizer? , 2003, Journal of Biological Chemistry.

[41]  M. Miyagi,et al.  Evidence that histidine protonation of receptor-bound anthrax protective antigen is a trigger for pore formation. , 2010, Biochemistry.

[42]  A. Lindberg,et al.  Characterization of a recombinant pneumolysin and its use as a protein carrier for pneumococcal type 18C conjugate vaccines , 1995, Infection and immunity.

[43]  Selection and evaluation of the immunogenicity of protective antigen mutants as anthrax vaccine candidates. , 2008, Vaccine.